Quantcast

Latest Non-small cell lung carcinoma Stories

2014-07-15 23:14:44

Targeted therapy for pancreatic cancer is based on personalized medicine approach Somerville, Massachusetts (PRWEB) July 15, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that Tozaride, the Company's lead candidate, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of pancreatic cancer. Pancreatic cancer is responsible for significant cancer...

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-03 12:23:38

TGEN Lung cancer patients could especially benefit from new ‘QTA’ technique Lung cancer patients could receive more precise treatment, and their progress could be better tracked, using a new high-tech method of non-invasive medical imaging analysis, according to a study published today by the journal PLOS ONE. Genetic changes increasingly are recognized as driving cancer development. But obtaining evidence of these changes usually requires a biopsy, which can be problematic for...

2014-07-01 16:30:23

Report Stems From National Grassroots Advocacy To Require New Strategic Plans Of Action To Address Deadliest Cancers WASHINGTON, July 1, 2014 /PRNewswire-USNewswire/ -- Today the National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. The report, entitled "Scientific Framework for Small Cell Lung Cancer (SCLC)" was...

2014-07-01 08:29:13

ORCA(TM) program includes seven Phase 2 trials in tumor types where patient need is acute, including bladder, lung, pancreas and prostate cancers BOTHELL, Wash. and VANCOUVER, British Columbia, July 1, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Cedar(TM) clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer....

2014-06-26 23:01:59

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR). Sacramento, CA (PRWEB) June 26, 2014 Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance...

2014-06-23 12:29:48

PARIS, June 23, 2014 /PRNewswire/ -- OSE Pharma SA receives a positive agreement to initiate a Phase 3 clinical trial with OSE-2101, a therapeutic cancer vaccine for non-small cell lung cancer (NSCLC) OSE Pharma SA, a European cancer immunotherapy company with a specific T cytotoxic technology, today announced that it has received positive feedback from an end of Phase 2 / Pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) and Scientific Advice from...

2014-06-19 12:30:33

Surveyed Payers Are Most Receptive to Therapies Offering a Median Overall Survival Benefit over Available Therapies, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 19, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, according to surveyed U.S. and European oncologists, improvement in efficacy endpoints are the most influential factors in prescribing decisions for previously treated EGFR wild-type/untested non-small-cell lung cancer (NSCLC). DRG...

2014-06-16 16:25:14

Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related